Clinical Trials Logo
  1. Home
  2. Biliary Cancer
  3. NCT02703714

Pembrolizumab and GM-CSF in Biliary Cancer

Biliary Cancer Clinical Trial

Official title:
Phase II Trial of Pembrolizumab (MK-3475) With GM-CSF Induction in Advanced Biliary Cancers

Clinical Trial Summary

This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at University of California, San Francisco (UCSF). This phase II study will examine the efficacy and safety of the novel combination of pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses that the combination may increase proportion of patients with overall response compared to contemporary historical controls, with acceptable safety.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02703714
Study type Interventional
Source University of California, San Francisco
Contact
Status Completed
Phase Phase 2
Start date May 6, 2016
Completion date December 31, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06101277 - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) N/A
Completed NCT02626195 - Preoperative Nutritional Support in Malnutritional Cancer Patients N/A
Completed NCT01401894 - Perception Prognosis, Goals of Treatment, and Communication N/A
Completed NCT00551096 - Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors Phase 1
Recruiting NCT04517448 - Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
Recruiting NCT04644068 - Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Phase 1/Phase 2
Recruiting NCT05849480 - A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) Phase 1/Phase 2
Completed NCT01853618 - Tremelimumab With Chemoembolization or Ablation for Liver Cancer Phase 1/Phase 2
Recruiting NCT05462314 - Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
Recruiting NCT05517811 - Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Active, not recruiting NCT01661114 - A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Phase 2
Recruiting NCT01859728 - GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Phase 2
Withdrawn NCT04480190 - Neoadjuvant Therapy in Biliary Adenocarcinoma Phase 1
Completed NCT00626158 - Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers Phase 1
Terminated NCT04566133 - Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). Phase 2
Completed NCT02930252 - Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. N/A
Recruiting NCT02628067 - Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Phase 2
Terminated NCT00868998 - GTX Regimen for Biliary Cancers Phase 2
Terminated NCT02908451 - A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer Phase 1
Terminated NCT01773785 - Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer Phase 2